Get to know and reach out to the experts at Profil.

Dr. Susanne Famulla Scientific Study Advisor Susanne is your contact partner, among others, for the following areas: Pharmacokinetics and Pharmacodynamics of Insulin Non-insulin adjunct therapies for type 1 diabetes Insulin induced lipohypertrophy

Short Bio

Susanne joined Profil’s Project Development Team as Scientific Study Advisor in October 2012. She is a chemist and has an academic background in basic science with focus on molecular biochemistry. In her PhD thesis at the German Diabetes Center in Düsseldorf, she investigated adipokine secretion from and inflammation of the adipose tissue and its potential role in obesity-induced diabetes mellitus.

At Profil, she is involved in the design and dissemination of clinical trials with a focus on investigating novel insulins and non-insulin adjunct therapies in subjects with type 1 diabetes mellitus. She is expert in pharmacodynamics and pharmacokinetics of novel insulin formulations as well as therapeutic approaches for treatment optimisation of type 1 diabetes.

Publications

Here are Susanne's recent publications:

• Andersen G, Meiffren G, Famulla S, Heise T, Ranson A, Seroussi C, Eloy R, Gaudier M, Charvet R, Chan Y-P, Soula O, DeVries JH. 
  ADO09, a co-formulation of the amylin-analog pramlintide and the insulin analog A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes (T1D).
  DIABETES OBES METAB 2020 Dec 18. doi: 10.1111/dom.14302. Online ahead of print. 
• Heise T, Norskov M, Nosek L, Kaplan K, Famulla S, Haahr HL.
  Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes.
  DIABETES OBES METAB 2017 Mar 14. doi: 10.1111/dom.12938 (Epub ahead of print)
• Famulla S, Hövelmann U, Fischer A, Coester HV, Hermanski L, Kaltheuner M, Kaltheuner L, Heinemann L, Heise T, Hirsch L.
  Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action, and impaired postprandial glucose control.
  DIABETES CARE 39: 1486-1492, 2016
• Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, Woerle HJ, Broedl UC, Kaspers S.
  Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
  DIABETES OBES METAB 2015. doi: 10.1111/dom.12494

Browse Profil's list of publications to see our other publications.

Selected Achievements and Work Experience